Phia Group Data Breach Claims Investigated by Lynch Carpenter

PITTSBURGH, Jan. 29, 2026 (GLOBE NEWSWIRE) -- The Phia Group (“Phia”), a healthcare consulting firm,1 recently announced a cybersecurity incident, which impacted the personal information of an unknown number of individuals. Lynch Carpenter, LLP is investigating claims against Phia related to this data breach. For an attorney to review your case, visit our site HERE.

In the incident, an unauthorized person gained access to Phia’s network and may have acquired records containing personally identifiable information (“PII”) and protected health information (“PHI”) that includes individuals’ names in combination with:

• dates of birth
• social security numbers
• drivers’ license or other government-issued ID numbers
• financial account information
• health insurance information
• medical information, including information about treatments, diagnoses, providers, and prescriptions

If your information was impacted in this incident, you may be entitled to compensation. For an attorney to review your case, visit our site HERE.

If you have received any other data breach notice letters in the last 30 days, please contact us here.

About Lynch Carpenter

Lynch Carpenter is a national class action law firm with offices in Pennsylvania, California, and Illinois. Our firm has represented millions of clients in data privacy matters for more than a decade and has earned national acclaim for complex litigation for plaintiffs across the country. To learn more, please visit www.lynchcarpenter.com.

For more information, please call Jerry Wells at (412) 322-9243, or email him at [email protected].

_______________________
1 https://www.phiagroup.com/about/

You May Also Be Interested In

• Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lu
• Solana Price Prediction Eyes $143 This Month as Remittix Reveals the Final $0.46 Presale Stage
• Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo